# Golidocitinib Plus CHOP in Newly Diagnosed PTCL

> **NCT06739265** · PHASE1,PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 68 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Golidocitinib plus CHOP

## Key facts

- **NCT ID:** NCT06739265
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06739265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06739265, "Golidocitinib Plus CHOP in Newly Diagnosed PTCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06739265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*